Single-Dose Pharmacokinetics and Safety of Daclatasvir in Subjects with Renal Function Impairment

Abstract

Observed DCV exposure increases were within the normal range of variability and were not associated with an elevated risk of adverse events. DCV can be administered in subjects with renal impairment, including ESRD, without dose modification. ClinicalTrials.gov NCT01830205.